DRD2 and schizophrenia: Partial agonism at dopamine D2 receptors (D2R) has been suggested to exert beneficial effects on schizophrenia, a chronic mental illness characterized by hypo- and hyperfunctions in monoamine neurotransmitter systems, including the mesolimbic and mesocortical dopaminergic pathways [9].